Synektik SA Adjusts Evaluation Amid Strong Financial Performance and Growth Outlook

Synektik SA, a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects the company's current financial metrics and market position, highlighting its robust operational performance. The stock's P/E ratio stands at 18, while the Price to Book Value is noted at 17.62. Additionally, Synektik SA's EV to EBIT is recorded at 14.43, and its EV to EBITDA is 13.01. The company showcases a PEG ratio of 0.31, indicating a favorable growth outlook relative to its valuation. With a dividend yield of 3.28%, the company has also demonstrated impressive returns on capital, with a ROCE of 120.86% and a ROE of 96.34%. Recent financial results for the quarter ending June 2026 reveal significant achievements, including an operating cash flow of PLN 176 million and net sales reaching PLN 292.26 million. The company has maintained a strong long-term fundamental strength, evidenced by a 74.80% CAGR growth in operating profits and a net-debt-free status. For more insights on Synektik SA's financial trend performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.